146 related articles for article (PubMed ID: 33164584)
1. Association of Exon 14 of the
Mohammadi Z; Mohammadi R; Haghpanah S; Moghadam M; Pazhoomand R; Karimi M
Hemoglobin; 2020 Nov; 44(6):406-410. PubMed ID: 33164584
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
3. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
4. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.
Banan M; Bayat H; Azarkeivan A; Mohammadparast S; Kamali K; Farashi S; Bayat N; Khani MH; Neishabury M; Najmabadi H
Hemoglobin; 2012; 36(4):371-80. PubMed ID: 22686296
[TBL] [Abstract][Full Text] [Related]
5. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
[TBL] [Abstract][Full Text] [Related]
8. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
9. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
10. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
Karimi M; Darzi H; Yavarian M
J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
13. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait.
Adekile AD; Azab AF; Al-Sharida SI; Al-Nafisi BA; Akbulut N; Marouf RA; Mustafa NY
Hemoglobin; 2015; 39(5):320-6. PubMed ID: 26076396
[TBL] [Abstract][Full Text] [Related]
15. Minimal doses of hydroxyurea for sickle cell disease.
Lima CS; Arruda VR; Costa FF; Saad ST
Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
17. The use of hydroxyurea in the real life of MIOT network: an observational study.
Ricchi P; Meloni A; Rigano P; Pistoia L; Spasiano A; Allò M; Messina G; Quarta A; Rosso R; Quota A; Filosa A; Maggio A; Pepe A
Expert Opin Drug Saf; 2022 Nov; 21(11):1433-1440. PubMed ID: 35435090
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of β-thalassemia.
Shariati L; Rohani F; Heidari Hafshejani N; Kouhpayeh S; Boshtam M; Mirian M; Rahimmanesh I; Hejazi Z; Modarres M; Pieper IL; Khanahmad H
J Cell Biochem; 2018 Nov; 119(11):9357-9363. PubMed ID: 30010219
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Hydoxyurea in Yemeni Transfusion-Dependent β-Thalassemia Patients.
Al-Nood HA; Al-Nood RM; Ghanem NS; Al-Hadi AM
Hemoglobin; 2020 Mar; 44(2):104-108. PubMed ID: 32308066
[TBL] [Abstract][Full Text] [Related]
20. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
Dover GJ
Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
